AU2022405026A1 - Alz-801 for use in treating alzheimer's disease - Google Patents
Alz-801 for use in treating alzheimer's disease Download PDFInfo
- Publication number
- AU2022405026A1 AU2022405026A1 AU2022405026A AU2022405026A AU2022405026A1 AU 2022405026 A1 AU2022405026 A1 AU 2022405026A1 AU 2022405026 A AU2022405026 A AU 2022405026A AU 2022405026 A AU2022405026 A AU 2022405026A AU 2022405026 A1 AU2022405026 A1 AU 2022405026A1
- Authority
- AU
- Australia
- Prior art keywords
- alz
- day
- subject
- dosage
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NRZRFNYKMSAZBI-ZETCQYMHSA-N 3-[[(2s)-2-amino-3-methylbutanoyl]amino]propane-1-sulfonic acid Chemical compound CC(C)[C@H](N)C(=O)NCCCS(O)(=O)=O NRZRFNYKMSAZBI-ZETCQYMHSA-N 0.000 title claims abstract description 113
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 68
- 230000001965 increasing effect Effects 0.000 claims abstract description 18
- 230000003247 decreasing effect Effects 0.000 claims description 27
- 230000004797 therapeutic response Effects 0.000 claims description 27
- 230000007423 decrease Effects 0.000 claims description 18
- 230000001149 cognitive effect Effects 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 7
- 206010001497 Agitation Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 230000001594 aberrant effect Effects 0.000 claims description 2
- 230000006399 behavior Effects 0.000 claims description 2
- 235000012631 food intake Nutrition 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 230000003252 repetitive effect Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 16
- 230000006999 cognitive decline Effects 0.000 description 9
- 208000010877 cognitive disease Diseases 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 8
- 230000006872 improvement Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 5
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Aminopropanesulfonate Chemical compound NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 description 4
- 229960003570 tramiprosate Drugs 0.000 description 4
- 230000001755 vocal effect Effects 0.000 description 4
- 230000019771 cognition Effects 0.000 description 3
- 230000005021 gait Effects 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 230000037081 physical activity Effects 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 2
- 208000027626 Neurocognitive disease Diseases 0.000 description 2
- 230000036626 alertness Effects 0.000 description 2
- 230000009133 cooperative interaction Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000008450 motivation Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 102100034112 Alkyldihydroxyacetonephosphate synthase, peroxisomal Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 101000799143 Homo sapiens Alkyldihydroxyacetonephosphate synthase, peroxisomal Proteins 0.000 description 1
- 238000000848 angular dependent Auger electron spectroscopy Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000037411 cognitive enhancing Effects 0.000 description 1
- 230000007370 cognitive improvement Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000051 modifying effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163287552P | 2021-12-09 | 2021-12-09 | |
| US63/287,552 | 2021-12-09 | ||
| PCT/US2022/052331 WO2023107658A1 (en) | 2021-12-09 | 2022-12-09 | Alz-801 for use in treating alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022405026A1 true AU2022405026A1 (en) | 2024-06-20 |
Family
ID=85157530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022405026A Pending AU2022405026A1 (en) | 2021-12-09 | 2022-12-09 | Alz-801 for use in treating alzheimer's disease |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250041248A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4444286A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024542844A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240116529A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118678950A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022405026A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3240392A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL313404A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024007070A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023107658A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3347002B1 (en) * | 2015-09-10 | 2023-06-07 | Alzheon, Inc. | Treatment of alzheimer's disease in a particular patient population |
| MX2021001287A (es) * | 2018-08-01 | 2021-07-15 | Alzheon Inc | Métodos para tratar trastornos neurodegenerativos. |
-
2022
- 2022-12-09 AU AU2022405026A patent/AU2022405026A1/en active Pending
- 2022-12-09 EP EP22851094.7A patent/EP4444286A1/en active Pending
- 2022-12-09 IL IL313404A patent/IL313404A/en unknown
- 2022-12-09 WO PCT/US2022/052331 patent/WO2023107658A1/en not_active Ceased
- 2022-12-09 MX MX2024007070A patent/MX2024007070A/es unknown
- 2022-12-09 CA CA3240392A patent/CA3240392A1/en active Pending
- 2022-12-09 JP JP2024534268A patent/JP2024542844A/ja active Pending
- 2022-12-09 US US18/717,139 patent/US20250041248A1/en active Pending
- 2022-12-09 CN CN202280091217.0A patent/CN118678950A/zh active Pending
- 2022-12-09 KR KR1020247022383A patent/KR20240116529A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4444286A1 (en) | 2024-10-16 |
| JP2024542844A (ja) | 2024-11-15 |
| KR20240116529A (ko) | 2024-07-29 |
| IL313404A (en) | 2024-08-01 |
| WO2023107658A1 (en) | 2023-06-15 |
| US20250041248A1 (en) | 2025-02-06 |
| MX2024007070A (es) | 2024-08-22 |
| CN118678950A (zh) | 2024-09-20 |
| CA3240392A1 (en) | 2023-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5289765B2 (ja) | 自閉症、強迫神経症、および衝動性の治療のためのメマンチン（ナメンダ）の使用 | |
| Shopsin et al. | Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients | |
| JP6895949B2 (ja) | フェンフルラミンを用いたレノックス・ガストー症候群の処置方法 | |
| KR20190142364A (ko) | 펜플루라민을 사용하여 두즈 증후군을 치료하는 방법 | |
| Blaszak et al. | The use of short-acting nifedipine in pediatric patients with hypertension | |
| EP4031119A1 (en) | Treatment of behavioral impairment in developmental and epileptic encephalopathy | |
| CA3075719A1 (en) | Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults | |
| Sydenstricker et al. | The effect of nicotinic acid in stupor, lethargy and various other psychiatric disorders | |
| AU2016226006A1 (en) | Method of treatment with tradipitant | |
| KR20170036116A (ko) | 간성 뇌병증의 치료방법 | |
| CN110279699A (zh) | 用锡泊芬治疗高胆红素血症的方法 | |
| TW202131910A (zh) | 使用mtorc1調節劑的治療方法 | |
| CN104582793A (zh) | 用拉喹莫德和氨吡啶的组合治疗多发性硬化症 | |
| MXPA03006411A (es) | Empleo de flumazenilo en la elaboracion de un medicamento para el tratamiento de la dependencia de alcohol. | |
| Fowler et al. | Water intoxication, psychosis, and inappropriate secretion of antidiuretic hormone | |
| US20250041248A1 (en) | Alz-801 for use in treating alzheimer's disease | |
| Hollander et al. | Pharmacologic approaches in the treatment of pathological gambling | |
| JUDAH et al. | Psychiatric response of geriatric-psychiatric patients to Mellaril (TP-21 Sandoz) | |
| González-Vílchez et al. | Conversion from immediate-release tacrolimus to prolonged-release tacrolimus in stable heart transplant patients: a retrospective study | |
| Sharan | Dependence syndrome and intoxication delirium associated with zolpidem | |
| JP2024508860A (ja) | 認知機能障害の処置のためのルバダキシスタットの使用 | |
| Lindeboom et al. | Deanol and physostigmine in the treatment of L‐dopa‐induced dyskinesias | |
| PFEFFER et al. | Multiple transfusions for schizophrenia | |
| Manto et al. | Hypoglycemia associated with phenytoin intoxication | |
| Haq et al. | Bipolar disorder and tuberous sclerosis complex: is it a mere coincidence? |